Comparison of the efficacy and safety of low molecular weight heparins for venous thromboembolism prophylaxis in medically ill patients

References

• Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th edn. American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141:e195-226S
   Web of Science ®Google Scholar
• Beckman MG, Hooper WC, Critchley SE, et al. Venous thromboembolism: a public health concern. Am J Prev Med 2010;38:S495-501
   PubMed Web of Science ®Google Scholar
• Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population based cohort study. Arch Intern Med 2000;160:761-8
   PubMed Web of Science ®Google Scholar
• Prandoni P, Lensing AW, Codo A, et al. The long term clinical course of acute deep vein thrombosis. Ann Intern Med 1996;125:1-7
   PubMed Web of Science ®Google Scholar
• Rico JI, Pitarch JV, Rocha E. Overview of Venous Thromboembolism. Drugs 2010;70:3-10
   Web of Science ®Google Scholar
• Eikelboom JW, Hankley GJ. Low molecular weight heparins and heparinoids. Med J Aust 2002;177:379-83
   PubMed Web of Science ®Google Scholar
• Quader MA, Stump LS, Sumpio B. Low molecular weight heparins: current use and indications. J Am Col Surg 1998;187:641-58
   PubMed Web of Science ®Google Scholar
• Maddineni J, Walenga JM, Jeske WP, et al. Product individuality of commercially available low-molecular weight heparins and their genetic versions: therapeutic implications. Clin Appl Thromb Hemost 2006;12:267-76
   PubMed Web of Science ®Google Scholar
• White RH, Ginsberg Js. Low-molecular weight heparins: are they all the same? Br J Haematol 2003;121:12
   PubMed Web of Science ®Google Scholar
• Bick RL, Faweed J. Low molecular weight heparins: differences and similarities in approved preparations in the United States. Clin Appl Thrombosis/Hemostasis 1999;5:S63-6
   PubMed Web of Science ®Google Scholar
• Phung OJ, Kaln SB, Cook DJ, Murah MH. Dosing frequency of unfractionated heparin thromboprophylaxis: a meta-analysis. Chest 2011;140:374-81
   PubMed Web of Science ®Google Scholar
• Alikhan R, Cohen AT. Heparin for the prevention of venous thromboembolism in general medical patients (excluding stroke and myocardial infarction). Cochrane Database of 11 Systematic Reviews 2009, Issue 3. Art. No.: CD003747. DOI:10.1002/14651858.CD003747.pub2
   Google Scholar
• Dentali F, Douketis JD, Gianni M, et al. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med 2007;146:278-88
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12
   PubMedGoogle Scholar
• Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105-24
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Ciminniello C, Goldhaber SZ, et al. Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med. 2011;365:2463-72
   PubMed Web of Science ®Google Scholar
• Riess H, Haas S, Tebbe U, et al. A randomized, double blind study of certoparin versus unfractionated heparin to prevent venous thromboembolic events in acutely ill, nonsurgical patients. J Thromb Haemost 2010;8:1209-15
   PubMed Web of Science ®Google Scholar
• Schellong SM, Haas S, Greinacher A, et al. An open-label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN. Expert Opin Pharmacother 2010;11:2953-61
   PubMed Web of Science ®Google Scholar
• Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomized placebo controlled trial. BMJ 2006;332:325-9
   PubMed Web of Science ®Google Scholar
• Lederle FA, Sacks JM, Fiore L, et al. The prophylaxis of medical patients for thromboembolism pilot study. Am J Med 2006;119:54-9
   PubMed Web of Science ®Google Scholar
• Mahe I, Bergmann JF, d’Azemar P, et al. Lack of effect of a low-molecular weight heparin (nadroparin) on mortality in bedridden medical in-patients: a prospective randomized double blind study. Eur J Clin Pharmacol 2005;61:347-51
   PubMed Web of Science ®Google Scholar
• Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention for venous thromboembolism in acutely ill medical patients. Circulation 2004;110:874-9
   PubMed Web of Science ®Google Scholar
• Gallus AS, Hirsh J, Tutle RJ, et al. Small subcutaneous doses of heparin in prevention of venous thrombosis. N Engl J Med 1973;288:545-51
   PubMed Web of Science ®Google Scholar
• Belch JJ, Lowe GD, Ward AG, et al. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scot Med J 1981;26:115-17
   PubMed Web of Science ®Google Scholar
• Dahan R, Houlbert D, Caulin C, et al. Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: a randomized double blind trial. Haemostasis 1986;16:159-64
   PubMedGoogle Scholar
• Ibarra-Perez C, Lau-Cortes E, Colmenero-Zubiate S, et al. Prevalence and prevention of deep venous thrombosis of the lower extremities in high-risk pulmonary patients. Angiology 1988;39:505-13
   PubMed Web of Science ®Google Scholar
• Forette B, Wolmark Y. Calcium nadroparin in the prevention of thromboembolic disease in elderly subjects. Study of tolerance. Presse Med 1995;24:567-71
   PubMed Web of Science ®Google Scholar
• Harenberg J, Kallenbach B, Martin U, et al. Randomized controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients. Thromb Res 1990;59:639-50
   PubMed Web of Science ®Google Scholar
• Bergmann JF, Neuhart E, et al. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. Thromb Haemost 1996;76:529-34
   PubMed Web of Science ®Google Scholar
• Gardlund B; for the Heparin Prophylaxis Group. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious disease. Lancet 1996;347:1357-61
   PubMed Web of Science ®Google Scholar
• Lechler E, Schramm W, Flosbach CW; The Prime Study Group. The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low molecular weight heparin (enoxaparin). Haemostasis 1996;26:19-56
   Google Scholar
• Samama MM, Cohen AT, Darmon JY, et al. Prophylaxis for medical patients with enoxaparin study group. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999;341:793-800
   PubMed Web of Science ®Google Scholar
• Fraisse F, Holzapfel L, Couland JM, et al. The Association of Non-University Affiliated Intensive Case Specialists Physicians of France. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. Am J Respir Crit Care Med 2000;161:1109-14
   PubMed Web of Science ®Google Scholar
• Kleber FX, Witt C, Vogel G, et al, THE-PRINCE Study Group. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 2003;145:614-21
   PubMed Web of Science ®Google Scholar
• Harenberg J, Roebruck P, Heene DL. Subcutaneous low-molecular weight heparin versus standard heparin and the prevention of thromboembolism in medical patients: The Heparin Study in Internal Medicine Group. Haemostasis 1996;26:127-39
   PubMedGoogle Scholar
• Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available at: www.cochrane-handbook.org [Last accessed 1 November 2012]
   Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91
   PubMed Web of Science ®Google Scholar
• Lumley T. Network meta-analysis for indirect treatment comparisons. Stats Med 2002;21:2313-24
   PubMed Web of Science ®Google Scholar
• Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health. 2011;14:417-28
   PubMed Web of Science ®Google Scholar
• Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 2011;14:429-37
   PubMed Web of Science ®Google Scholar
• Carson W, Schilling B, Simons R, et al. Comparative effectiveness of dalteparin and enoxaparin in the hospital setting. J Pharm Pract 2012;25:180-9
   PubMedGoogle Scholar